argenx (ARGX) vs Krystal Biotech (KRYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Krystal Biotech (KRYS) has outperformed argenx (ARGX) over the past year, gaining 74.9% versus a gain of 2.5%. Over five years, KRYS leads with a +571.8% price change compared with +178.7% for ARGX. argenx is the larger company by market cap ($51.51 billion vs $9.75 billion), about 5.3 times the size.
On valuation, argenx trades at a lower forward P/E (23.6x vs 35.6x for Krystal Biotech).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | KRYS |
|---|---|---|
| Share price | $819.17 | $329.53 |
| Market cap | $51.51B | $9.75B |
| 1-day change | +0.07% | +0.68% |
| YTD return | -2.65% | +32.76% |
| 1-year return | +2.46% | +74.86% |
| 5-year return | +178.69% | +571.80% |
| P/E ratio (TTM) | 31.22 | 41.29 |
| Forward P/E | 23.59 | 35.56 |
| EPS (TTM) | $26.24 | $7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $389.13M |
| Revenue growth (YoY) | — | +33.94% |
| Net income (latest FY) | $1.29B | $204.83M |
| Operating margin | — | 41.45% |
| Net margin | — | 52.64% |
| 52-week high | $1,072.75 | $382.54 |
| 52-week low | $661.85 | $179.19 |
| Distance from 52-week high | -23.64% | -13.86% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +43.07% | +18.99% |
| Average volume | 317.26K | 381.18K |
| Shares outstanding | 62.89M | 29.60M |
| Employees | 1,863 | 295 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- argenx is about 5.3 times larger than Krystal Biotech by market value ($51.51B vs $9.75B).
- KRYS has outperformed ARGX by 72.4 percentage points over the past year.
- Krystal Biotech trades at a higher earnings multiple (41.3x vs 31.2x trailing P/E).
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
ARGX vs KRYS FAQ
Which is bigger, argenx or Krystal Biotech?
argenx (ARGX) is larger, with a market capitalization of $51.51B compared with $9.75B for Krystal Biotech (KRYS).
Which stock has performed better over the past year, ARGX or KRYS?
KRYS returned +74.86% over the past 12 months, compared with +2.46% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARGX or KRYS?
ARGX has the lower trailing P/E at 31.2, versus 41.3 for KRYS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are argenx and Krystal Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.